Economic analysis: Erlotinib marginally cost-effective
Wednesday, February 17, 2010 - 08:29
in Health & Medicine
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial data were reported in a new study published online February 16 in the Journal of the National Cancer Institute...